Type 2 cytokines and scleroderma interstitial lung disease

被引:0
|
作者
Chiara Pellicano
Lorenzo Vantaggio
Amalia Colalillo
Krizia Pocino
Valerio Basile
Mariapaola Marino
Umberto Basile
Edoardo Rosato
机构
[1] Sapienza University of Rome,Department of Translational and Precision Medicine
[2] UOC of Clinical Pathology,Clinical Pathology Unit and Cancer Biobank, Department of Research and Advanced Technologies
[3] General Hospital San Pietro Fatebenefratelli,Department of Translational Medicine and Surgery
[4] IRCCS Regina Elena National Cancer Institute,undefined
[5] Università Cattolica del Sacro Cuore,undefined
[6] Fondazione Policlinico A. Gemelli IRCCS,undefined
[7] UOC Clinical Pathology DEA II Level,undefined
[8] Hospital Santa Maria Goretti-ASL Latina,undefined
来源
关键词
Systemic sclerosis; Interstitial lung disease; Th2 cytokines; Ground glass; CALIPER;
D O I
暂无
中图分类号
学科分类号
摘要
Interstitial lung disease (ILD) is a life-threatening complication of systemic sclerosis (SSc). Type 2 (Th2) cytokines play a pivotal role in airway disease. Study aim was to evaluate serum level of Th2 interleukin (IL) and chemokine in SSc-ILD. Serum levels of IL-4, IL-5, IL-11, IL-13, IL-21, IL-31 and CXCL-13 were measured by Bio-Plex Multiplex Immunoassays in 60 SSc patients and 20 healthy controls (HC). Pulmonary function tests with diffusion lung capacity for carbon monoxide (DLco) and high resolution computed tomography (HRCT) were performed in SSc patients. ILD is defined as fibrotic changes (ground glass, reticular and honeycombing), assessed by Computer-Aided Lung Informatics for Pathology Evaluation and Ratings (CALIPER) software, affecting at least 10% of the lungs. Serum levels of Th2 cytokines were higher in SSc patients than HC. A linear correlation was observed between ground glass and IL-13 (r = 0.342, p < 0.01), IL-21 (r = 0.345, p < 0.01), IL-31 (r = 0.473, p < 0.001), IL-4 (r = 0.863, p < 0.001), IL-5 (r = 0.249, p < 0.05) and peripheral blood eosinophils (r = 0.463, p < 0.001). We found a negative correlation between DLco and IL-4 (r =  − 0.511, p < 0.001) and peripheral blood eosinophils (r =  − 0.446, p < 0.001). In the logistic regression analysis, IL-4 is associated with DLco ≤ 60% of the predicted [OR 1.039 (CI 95%: 1.015–1.064), p < 0.001], whilst mRSS [OR 1.138 (CI 95%: 1.023–1.266), p < 0.05] and IL-4 [OR 1.017 (CI 95%: 1–1.034), p < 0.05] were associated with ILD. Th2 inflammation could play a key role in early phase of SSc-ILD.
引用
收藏
页码:3517 / 3525
页数:8
相关论文
共 50 条
  • [31] THE PATTERN OF INTERSTITIAL LUNG-DISEASE IN SCLERODERMA AND SIOGRENS SYNDROME
    CAIRNS, DR
    SZENTIRMAY, A
    YEATES, M
    FERNANDEZ, V
    GIBSON, PG
    BRYANT, DH
    WACHER, T
    PENNY, R
    BREIT, SN
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1988, 18 (03): : 554 - 554
  • [32] Lessons from scleroderma: treatment of interstitial lung disease in SLE
    Distler, Oliver
    LUPUS SCIENCE & MEDICINE, 2021, 8 (SUPPL_1): : A5 - A5
  • [33] Determining progression of scleroderma-related interstitial lung disease
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    Sim, Myung
    Kim, Grace Hyun
    Goldin, Jonathan
    Clements, Philip J.
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2019, 4 (01) : 62 - 70
  • [34] INTERSTITIAL LUNG-DISEASE IN SCLERODERMA - ANALYSIS BY BRONCHOALVEOLAR LAVAGE
    SILVER, RM
    METCALF, JF
    STANLEY, JH
    LEROY, EC
    ARTHRITIS AND RHEUMATISM, 1984, 27 (11): : 1254 - 1262
  • [35] Scleroderma patients with combined pulmonary hypertension and interstitial lung disease
    Chang, B
    Wigley, FM
    White, B
    Wise, RA
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (11) : 2398 - 2405
  • [36] Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease
    Strange, Charlie
    Bolster, Marcy B.
    Roth, Michael D.
    Silver, Richard M.
    Theodore, Arthur
    Goldin, Jonathan
    Clements, Philip
    Chung, Joanie
    Elashoff, Robert M.
    Suh, Robert
    Smith, Edwin A.
    Furst, Daniel E.
    Tashkin, Donald P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (01) : 91 - 98
  • [37] Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease
    De Santis, Maria
    Bosello, Silvia Laura
    Peluso, Giusy
    Pinnelli, Michela
    Alivernini, Stefano
    Zizzo, Gaetano
    Bocci, Mario
    Capacci, Annunziata
    La Torre, Giuseppe
    Mannocci, Alice
    Pagliari, Gabriella
    Varone, Francesco
    Pistelli, Roberto
    Danza, Francesco Maria
    Ferraccioli, Gianfranco
    CLINICAL RESPIRATORY JOURNAL, 2012, 6 (01): : 9 - 17
  • [38] VERIFICATION OF GENETIC ASSOCIATIONS WITH SCLERODERMA ASSOCIATED INTERSTITIAL LUNG DISEASE
    Stock, C. J. W.
    DeLauretis, A.
    Visca, D.
    Daccord, C.
    Kokosi, M.
    Kouranos, V.
    Margaritopoulos, G.
    George, P. M.
    Molyneaux, P. L.
    Chua, F.
    Maher, T. M.
    Abraham, D. J.
    Denton, C. P.
    Ong, V.
    Wells, A. U.
    Renzoni, E. A.
    THORAX, 2019, 74 : A46 - A46
  • [39] Mycophenolate mofetil for scleroderma-related interstitial lung disease
    Zaheen, Ahmad
    Stanbrook, Matthew B.
    Anand, Anju
    LANCET RESPIRATORY MEDICINE, 2016, 4 (11): : E53 - E53
  • [40] INTERSTITIAL LUNG-DISEASE IN SCLERODERMA - ROLE OF PENICILLAMINE THERAPY
    DECLERCK, LS
    DEQUEKER, J
    FRANCX, L
    DEMEDTS, M
    EUROPEAN RESPIRATORY JOURNAL, 1988, 1 (04) : 393 - 393